Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Isolated hyperthermic perfusions for cutaneous melanoma in-transit me… Isolated Limb Infusion · PMID 37843790 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients w… | Clinical & experimental metastasis 2026-08-16 13:15:46 | Source |
| Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivo… Isolated Limb Infusion · PMID 39417680 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Intratumoral tavokinogene telseplasmid delivered by electroporation (TAVO-EP) results in localized expression of IL-12… | Clinical cancer research : an official journal of the… 2026-08-16 13:15:46 | Source |
| Human Embryoid Body-Based Assays for Preclinical Screening of Potenti… Adefovir Dipivoxil and Lamivudine · PMID 40965318 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Ensuring the safety of drugs during pregnancy is a critical concern in clinical practice. Animal tests are not always r… | Stem cells and development 2026-08-16 13:15:45 | Source |
| [Compare the effect of combined therapy between telbivudine plus adef… Adefovir Dipivoxil and Lamivudine · PMID 29996341 | Cancer | À vérifier | Publication | PubMed | Voir la publication source To compare the effect of combined therapy using lamivudine (LAM) plus adefovir (ADV) versus telbivudine (LdT) plus adef… | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing z… 2026-08-16 13:15:45 | Source |
| [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chro… Adefovir Dipivoxil and Lamivudine · PMID 30616314 | Cancer | À vérifier | Publication | PubMed | Voir la publication source To analyze the therapeutic effect on HBeAg-negative chronic hepatitis B patients treated with Peg-IFNα-2a combined with… | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing z… 2026-08-16 13:15:45 | Source |
| CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-… ET1402L1-ARTEMIS™ T cells -Intratumoral Injections · PMID 42250288 | Cancer | Thérapie cellulaire | Publication | PubMed | Voir la publication source Solid tumors remain refractory to chimeric antigen receptor (CAR) T cell therapy largely because they fail to infiltrat… | International immunopharmacology 2026-08-16 13:15:37 | Source |
| Modulated electro-hyperthermia enhances tumor cell susceptibility to… ET1402L1-ARTEMIS™ T cells -Intratumoral Injections · PMID 42338164 | Cancer | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Numerous studies have reported γδ T cell therapy as a promising immunotherapeutic strategy for cancer treatment; howeve… | International journal of hyperthermia : the official j… 2026-08-16 13:15:37 | Source |
| Prolonged intratumoral treatment with TLR7/8 agonist R848 regulates t… ET1402L1-ARTEMIS™ T cells -Intratumoral Injections · PMID 42124329 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Toll-like receptor 7/8 agonists (TLR7/8a), such as resiquimod (R848), are highly potent in activating dendritic cells a… | Cancer biology & therapy 2026-08-16 13:15:37 | Source |
| Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes wav… ET1402L1-ARTEMIS™ T cells -IV · PMID 41566607 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Since its emergence in late 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has continuously threate… | Emerging microbes & infections 2026-08-16 13:15:35 | Source |
| Immune evasion in locally advanced mismatch repair-deficient microsat… ET1402L1-ARTEMIS™ T cells -IV · PMID 42424525 | Cancer | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Early-stage colorectal cancer (CRC) with confirmed microsatellite instability generally has a favorable prognosis assoc… | Oncoimmunology 2026-08-16 13:15:35 | Source |
| Novel captopril-valproic acid platinum(IV) hybrids with potent antipr… ET1402L1-ARTEMIS™ T cells -IV · PMID 42288028 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Fibrosis and DNA repair are crucial factors for cancer development and metastasis. Here, three-component platinum(IV) h… | European journal of medicinal chemistry 2026-08-16 13:15:35 | Source |
| Comparison of implant stability and peri-implant bone changes followi… Implant placement · PMID 42235675 | Cancer | À vérifier | Publication | PubMed | Voir la publication source To compare implant stability and peri‑implant bone changes between two bone-level implant systems placed simultaneously… | Journal of dentistry 2026-08-16 13:15:34 | Source |
| Maxillary anterior horizontal ridge reconstruction using computer-gui… Implant placement · PMID 42419681 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source This randomized clinical study aimed to assess implant placement accuracy and radiographic outcomes of computer-guided… | Journal of dentistry 2026-08-16 13:15:34 | Source |
| Robot-assisted haptic guidance in endodontics: A pilot study evaluati… Implant placement · PMID 42336075 | Cancer | À vérifier | Publication | PubMed | Voir la publication source A robot-assisted haptic guidance system (RA) has recently been introduced to facilitate implant placement. Unlike dynam… | Journal of dentistry 2026-08-16 13:15:34 | Source |
| Interleukin-2 is associated with cytopenias in systemic lupus erythem… IL-2 · PMID 42501014 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Interleukin 2 (IL-2) is a cytokine essential for the development and function of regulatory T cells, which are key play… | Autoimmunity 2026-08-16 13:15:33 | Source |
| Intratumoral enrichment and suppressive activity of DP8α regulatory T… IL-2 · PMID 42393838 | Cancer | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Colorectal cancer (CRC) progression is driven by dynamic interactions among tumor cells, immune infiltrates, and the gu… | Oncoimmunology 2026-08-16 13:15:33 | Source |
| Sialic acid -ligand dynamics modulate Siglec-7 and -9 function and af… IL-2 · PMID 41928453 | Cancer | À vérifier | Publication | PubMed | Voir la publication source The glyco-immune checkpoints Siglec-7 and Siglec-9 have received considerable interest as targets for cancer immunother… | Oncoimmunology 2026-08-16 13:15:33 | Source |
| Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific im… Dendritic Cells (DC) malignant melanoma · PMID 42519394 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source In recent years, activation of the immune system has been recognized as a key mechanism in supporting the therapeutic o… | Molecular therapy. Oncology 2026-08-16 13:15:32 | Source |
| Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist t… Dendritic Cells (DC) malignant melanoma · PMID 42093471 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) b… | Oncoimmunology 2026-08-16 13:15:32 | Source |
| Enhancing the evidence for opioid-free anaesthesia in the elderly: a… Opioid free anesthetics · PMID 41821494 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Annals of medicine 2026-08-16 13:15:31 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||